M<sup>3</sup>RNA Drives Targeted Gene Delivery in Acute Myocardial Infarction.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30047313.
- Also identified by DOI 10.1089/ten.TEA.2017.0445 and PMC identifier 6352545.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The M<sup>3</sup>RNA (microencapsulated modified messenger RNA) platform is an approach to deliver messenger RNA (mRNA) in vivo, achieving a nonintegrating and viral-free approach to gene therapy. This technology was, in this study, tested for its utility in the myocardium, providing a unique avenue for targeted gene delivery into the freshly infarcted myocardial tissue. This study provides the evidentiary basis for the use of M<sup>3</sup>RNA in the heart through depiction of its performance in cultured cells, healthy rodent myocardium, and acutely injured porcine hearts. By testing the technology in large animal models of infarction, compatibility of M<sup>3</sup>RNA with current coronary intervention procedures was verified.
Medical subject headings
- Gene Transfer Techniques
- Myocardial Infarction
- Myocytes, Cardiac
- RNA, Messenger